Workup for Acute Weakness and Confusion in Chemotherapy Patients
Immediately assess for life-threatening metabolic derangements (hypercalcemia, hyponatremia/SIADH, hypomagnesemia), chemotherapy-induced encephalopathy, and posterior reversible encephalopathy syndrome (PRES), as these are the most common and reversible causes of acute neurological deterioration in this population 1, 2.
Initial Diagnostic Approach
Priority Laboratory Studies
Obtain the following labs emergently to identify reversible metabolic causes:
- Serum calcium - Hypercalcemia causes confusion and altered consciousness; common in malignancy 2
- Serum sodium and osmolality - SIADH is associated with platinum-based chemotherapy, vinca alkaloids, and small cell lung cancer 2
- Serum magnesium - Hypomagnesemia from cisplatin or cetuximab causes confusion, hallucinations, and seizures 2
- Complete blood count - Assess for neutropenic sepsis
- Blood cultures if febrile - Septic encephalopathy is a critical differential 1
Neuroimaging
Obtain brain MRI with T2-weighted and diffusion-weighted sequences to evaluate for:
- PRES - Bilateral parietal-occipital white matter vasogenic edema on T2-weighted imaging 1
- Chemotherapy-induced leukoencephalopathy - Symmetric white matter lesions, especially parietal/occipital 3
- Brain metastases - May present with focal deficits or altered consciousness 4, 5
- Hemorrhage or ischemia 4
Specific Chemotherapy-Related Considerations
Identify the Offending Agent
Review recent chemotherapy regimen for high-risk agents:
- Ifosfamide - Causes acute encephalopathy with confusion, drowsiness to coma; typically reversible with discontinuation 1
- Capecitabine, topotecan - Cross blood-brain barrier and cause delirium 2
- 5-fluorouracil - Can cause leukoencephalopathy with seizures and confusion 3
- Platinum agents - Associated with SIADH and hypomagnesemia 2
- Immunotherapies - Cytokine release causes neurological symptoms 2
Blood Pressure Assessment
Measure blood pressure urgently - Hypertension is a critical risk factor for PRES, especially in patients receiving high-dose chemotherapy, stem-cell transplantation, or immunosuppression 1. PRES requires immediate blood pressure control.
Clinical Presentation Patterns
Distinguish between syndromes based on presentation:
- Acute encephalopathy: Impaired attention to delirium, psychotic symptoms, apathy, agitation; may include focal signs like paresis or seizures 1
- PRES: Acute onset with visual disturbances/blindness, headaches, seizures, altered consciousness 1
- Metabolic causes: Hypomagnesemia presents with irritability, nystagmus, seizures, severe pain; hypercalcemia with confusion; SIADH with euvolemic hyponatremia 2
Critical Pitfalls to Avoid
Do not attribute symptoms solely to "chemobrain" - This guideline explicitly excludes chronic cognitive impairment from the acute workup 1. Acute weakness and confusion demand immediate evaluation for reversible causes.
Do not delay imaging if focal signs or seizures are present - These suggest structural lesions (metastases, hemorrhage) or PRES requiring urgent intervention 1, 5.
Do not overlook medication review - Many supportive medications (opioids, NSAIDs, anticonvulsants, antidepressants) can contribute to SIADH 2.
Immediate Management Based on Findings
If Metabolic Abnormality Identified:
- Hypercalcemia: Initiate IV bisphosphonates (zoledronic acid 4 mg) 2
- SIADH: Discontinue implicated medications, fluid restriction, adequate oral salt intake 2
- Hypomagnesemia: IV magnesium sulfate replacement 2
If Chemotherapy-Induced:
- Discontinue the offending agent immediately 2
- For ifosfamide encephalopathy: Correct electrolytes, give benzodiazepines for symptoms; expect spontaneous full remission 1
If PRES Confirmed:
- Stringent blood pressure control 1
- Cease anticancer therapy 1
- Antiepileptic treatment if seizures present 1
The workup must be rapid and systematic, as most causes are reversible with prompt intervention, but delays can result in permanent neurological sequelae or death.